Molecule to Market: Inside the outsourcing space

Expanding drug dosage possibilities…

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Megan Greth, Director of Marketing & Business Development and Tadgh Prendeville, General Manager at ARx LLC.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Megan and Tadgh, covering:

•     The developments & demands for new transdermal drug products and oral thin films as a more patient centric drug delivery platform.
•     How the focus on Covid-19 related vaccines directly impacted the drug product supply chain.
•     ‘Lean’ observations on the speed (or not) of the pharma manufacturing sector.
•     Reflections on the career ‘ride’ and the sectors core focus – making drugs for sick people.
•     Learning to not sweat the small stuff and to ride out any storms.
•     Chicken-and-egg capacity and capability challenges for CDMO investment as clients edge closer to commercial approval.

 

Who are the ARx duo?

With a Bachelor of Science, Megan has been in the sector for around 15 years. She is now responsible for market assessment and strategic selection of new projects that will benefit from ARx’s drug delivery technologies. Whilst Tadgh has a background in bioengineering and has worked in manufacturing and operations and as a lean consultant, before progressing to his current role as head of ARx.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

From Teesside Uni to global leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jarlath Keating President & CEO at ABL Inc.

Jarlath has over 25 years of global life science industry experience. Starting his career in the UK in the early 90’s before transitioning to the US in 2009. During this time, Jarlath worked for HyClone and Lonza Biologics. He served as the Vice President of Global Commercial Operations for MilliporeSigma’s Process Solutions Services division, leading the BioReliance® biological safety testing and biomanufacturing divisions. He now leads ABL, globally.

Your host, Raman Sehgal, leads a conversation on the pharmaceutical and biotechnology supply chain, transitioning from ‘shop floor’ to CEO, and the impact of COVID-19 from a manufacturing point of view. Hear Jarlath’s thoughts on:

•     The importance of leaders building knowledge across the whole business.
•     Understanding the jigsaw - your success is dependent upon the success of your colleagues.
•     Taking opportunities, leaning into risk, and backing yourself through belief and hard work.
•     The evolution of the gene therapy and cell therapy space, and the operational challenges it brings.
•     How contract service providers must anticipate rather than react to future pandemics and new areas of development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The accidental CDMO

In this episode of Molecule to Market, your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Richard Johnson, Founding Director of Upperton Pharma Solutions. With more than 25 years of experience in the industry, Richard is a founding director of two, successful pharmaceutical companies. He has authored 30 scientific publications and is the named-inventor on more than 20 patents. His research experience spans a broad range of scientific disciplines particularly in the field of pharmaceutical spray drying and drug delivery. This knowledge has been used in the successful development of a number of pharmaceutical products from early research to testing on patients.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:

• Greater collaboration and alliance between smaller, specialist early phase contract service providers as a way to compete against the global one-stop-shops.
• Increased demand for nasal and pulmonary delivery as a result oft the pandemic. And why Richard was not surprised to see a Covid-19 vaccine developed so quickly.
• The contrast of founding a steady 20-year growth business and the another that exited in just five years.
• The increasing demand and application for spray drying technology to solve modern pharmaceutical development challenges.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

 

The passionate problem solver

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Robert Lee Ph.D., President at the CDMO Division of Lubrizol Life Science Health (LLS). Rob has over 30 years’ experience in the pharmaceutical R&D space and his areas of expertise include drug delivery, formulation development, analytical sciences and sterile manufacturing. With a Ph.D. in Physical Bioorganic Chemistry, Rob has published more than three dozen articles and five book chapters. Plus, he holds 11 issued patents and 15 provisional or PCT patent applications. He has worked for some major companies in the sector and was appointed President of the CDMO Division of LLS after 10 years with the business.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob Lee, covering the new paradigm for drug development and manufacturing after the speed to market achieved by the COVID-19 vaccines. Rob then explains how patient-friendly dosage forms will continue to play an increasingly important role in the future. Rob also gives us an idea of the types of molecules and projects coming through the pipeline at the moment and what is in store for LLS. Lastly Rob shares what it’s been like to transition from a scientist to a leader while keeping science at the heart of everything he does. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The entrepreneurial scientist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Vice President of Life Sciences at Egnyte and the founder of the Biotech 2050 podcast. Alok has a very impressive academic and entrepreneurial background in life sciences, before running the fast-growing life science division at Egnyte, he was a Co-Founder of PreScouter and TetraScience, raising millions along the way. Having completed a postdoctoral fellowship at Harvard University, he has also been published in Forbes and Nature.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole loaf more) with Alok, covering how he founded, built and scaled two life science software companies… and then did it all over again as a vertical of a larger organisation. Alok shares the lessons he learned while raising millions in VC capital and the value of building relationships early on. He explains how CDMOs and CROs can become more strategic with biotech clients by seeing themselves as data and knowhow specialists. Finally, Raman and Alok discuss the journey of the contract services space and how the landscape has shifted from a largely transactional rigid business to becoming the foundational bedrock of the life science domain. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The sales guru

In this episode of Molecule to Market, we do things a little differently with an experimental episode. You’ll go inside the outsourcing space of the global drug development sector with the best-selling sales author, Ian Altman. 

 

Ian started, sold, and grew his prior companies from zero to over one billion dollars in value. He’s a co-author of the bestseller, Same Side Selling, now in its second edition. He is the author of hundreds of articles on Forbes and Inc. Ian is recognized as one of the world’s Top 30 Global Gurus on Sales, and his Same Side Selling Academy is ranked in the top 5 globally for Sales Development Programs.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Ian Altman discussing “becoming a magnet for your client’s problem” while also making sure the client has a problem worth solving. Ian speaks on the importance of role-playing, practising and rehearsing sales scenarios. He explains the need to aim for the ‘engage’ level with potential clients in order to secure the next pharma or biotech deal. Lastly, Ian explains the importance of understanding your client’s Elevator Rant and the emotion and impact of not solving their issue.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Marathons. Wine. And 30 years in healthcare.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Marco Chiado’ Piat, President, at Terumo Pharmaceutical Solutions part of Terumo. Marco has worked in the pharma and healthcare sector since the early 1990s. His impressive experience has included eight years at McKinsey before he founded a VC business. He then had several senior roles at medical device specialist LivaNova before joining Terumo Pharmaceutical Solutions in 2017, where he has risen to the top. If that was not enough, he’s an accomplished marathon runner and runs a winery in Northern Italy with his brother.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Marco Chiado’ Piat covering the importance of passion, curiosity and simply liking what you do as important pillars for serving your purpose. Marco explains how running marathons and ultra marathons has not only helped train his body for resistance but has also trained his mind for resilience. He tells Raman of the unrest Covid has caused medical device companies, and the apparent value of long term thinking that is inherent in the pharmaceutical sector. Marco closes with the importance of being ready for the unknown and unforeseen by having an ‘agility muscle’ ready to flex into action.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The industry guru

In this one hour special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Miller. If you’ve worked in the bio and pharmaceutical CDMO space for a few years, then there’s a very good chance you will know my guest today. Jim is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s an industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering how his husband & wife start-up business helped put the industry on the map while providing CMOs/CDMOs with invaluable drug pipeline intel. He explains how CDMOs have enabled the success of the explosion of emerging biopharma in the last 10 years, helping them turn IP into product. He also gives his expert take on the changing role of CDMOs in Asia and whether we will see any APIs bounce back to North America and Europe. Lastly he covers the robustness of the market post Covid-19 and whether to expect to see a financial dip or not.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

10 Trends for 2021

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with... Raman Sehgal, founder of ramarketing and the Molecule to Market podcast.

Your host, Raman shares ten trends that he expects to see in 2021 and beyond based on themes from podcast interviews and expert insights gathered in 2020.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The CDMO Disrupter

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tia Lyles-Williams, CEO of LucasPye Bio. Tia is the first African-American Queer Woman to own & lead a Biopharma Large-Scale Manufacturing Company in the US. She has spent 20 years in the industry formerly working for the U.S. Federal Government, Big Pharma and Small Biotech Companies, before setting up her own CDMO. Tia is not only highly knowledgeable about the biotechnology sector but she works hard on helping economic development in underserved communities.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tia, covering how equality and diversity in the pharma and biotech space is no better now than it was 20 years ago, which is being compounded by Covid-19. She describes the challenges of fundraising and getting a biotech CDMO built and off the ground in an economically underserved community in Philadelphia. She stresses the importance in young people taking their education and experience into their own hands and going the extra mile to unlock new opportunities, “don’t ask permission to lead” she says. Lastly, Tia speaks on creating a new breed of CDMOs, organizations that are highly digital, leaner, faster, cheaper, and more transparent with a social conscience. She also wants to put Pennsylvania on the map as the next major global life science biotech hub.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.